• Independent validation of Ultranode® 95 in commercial cell format
• New product launches and expanded product portfolio
• Strengthened balance sheet with A$10.0 million raised from option exercise
• New distribution and collaboration agreements in Japan and South Korea
• Continued growth in Life Sciences revenue and partnerships

AnteoTech Ltd, a supplier of chemicals and advanced material solutions for the Lithium-ion Battery and Life Sciences markets, has reported significant progress for the quarter ended 30 June 2026. Key highlights include the independent validation of Ultranode® 95 high silicon anode in a commercial cell format, the launch of a new ABT product, and new international distribution and collaboration partners in Japan and South Korea. The full exercise of listed ADOO options raised approximately A$10.0 million, strengthening the company's cash position. In the Life Sciences segment, the company appointed a new distributor in Japan and completed the initial stage of a CLIA product development program. The company also recognized A$61,595 in related revenue and shipped $134,138 of AnteoBind® product to the Serum Institute of India.

A$10.0 million raised from option exercise, A$61,595 in CLIA-related revenue

AnteoTech is optimistic about converting technical and commercial progress into sales in FY2027, with continued demand for its products and expanded market reach.